Dr. Lynch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3500 Civic Center Blvd
Philadelphia, PA 19104Phone+1 215-590-1000- Is this information wrong?
Education & Training
- Johns Hopkins University School of MedicineClass of 1988
Certifications & Licensure
- FL State Medical License 2021 - Present
- MD State Medical License 2022 - 2024
- VA State Medical License 2021 - 2024
- PA State Medical License 1990 - 2024
- NY State Medical License 2021 - 2024
- NC State Medical License 2020 - 2022
- OH State Medical License 1990 - 2014
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Start of enrollment: 2007 Dec 01
- Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Start of enrollment: 2008 Jul 01
- Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Start of enrollment: 2009 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.Katherine Gunther, David R Lynch> ;Expert Opinion on Pharmacotherapy. 2024 Apr 18
- Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study.Christian Rummey, Sub H Subramony, Jennifer Farmer, Susan Perlman, David R Lynch> ;Annals of Clinical and Translational Neurology. 2024 Mar 31
- De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor.Yuchen Xu, Rui Song, Riley E Perszyk, Wenjuan Chen, Sukhan Kim, Kristen L Park, James P Allen, Kelsey A Nocilla, Jing Zhang, Wenshu XiangWei, Anel Tankovic, Ellington ...> ;Cellular and Molecular Life Sciences. 2024 Mar 28
- Join now to see all
Press Mentions
- Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)September 15th, 2021
- Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development ProgramsAugust 9th, 2021
- Could Statins Ease Deadly Heart Condition in Friedreich’s Ataxia?April 17th, 2018
Grant Support
- Nicotinic-Glutamatergic Interactions In Axonal DevelopmentNational Institute Of Neurological Disorders And Stroke2011
- Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2008–2011
- Defining The Epitope In Antinmda Receptor EncephalitisNational Institute Of Neurological Disorders And Stroke2009–2010
- Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2007
- Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2004–2006
- Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2003
- NMDA Receptors, Protein Kinase C, And ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1999–2002
- PCP And The NMDA ReceptorNational Institute On Drug Abuse1996–1999
- Biochemical Approach To NMDA Receptors &ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1995–1999
- NMDA Receptors--Biochemical Definition And Pharmacological CharacterizationEunice Kennedy Shriver National Institute Of Child Health &Human Development1995–1999
Hospital Affiliations
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
- Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: